PT68071B - Process for preparing hydantoin therapeutic agents - Google Patents

Process for preparing hydantoin therapeutic agents

Info

Publication number
PT68071B
PT68071B PT68071A PT6807178A PT68071B PT 68071 B PT68071 B PT 68071B PT 68071 A PT68071 A PT 68071A PT 6807178 A PT6807178 A PT 6807178A PT 68071 B PT68071 B PT 68071B
Authority
PT
Portugal
Prior art keywords
therapeutic agents
hydantoin
preparing
preparing hydantoin
therapeutic
Prior art date
Application number
PT68071A
Other languages
English (en)
Other versions
PT68071A (en
Inventor
Reinhard Sarges
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PT68071A publication Critical patent/PT68071A/pt
Publication of PT68071B publication Critical patent/PT68071B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PT68071A 1977-05-23 1978-05-22 Process for preparing hydantoin therapeutic agents PT68071B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/799,586 US4130714A (en) 1977-05-23 1977-05-23 Hydantoin therapeutic agents

Publications (2)

Publication Number Publication Date
PT68071A PT68071A (en) 1978-06-01
PT68071B true PT68071B (en) 1979-10-26

Family

ID=25176274

Family Applications (1)

Application Number Title Priority Date Filing Date
PT68071A PT68071B (en) 1977-05-23 1978-05-22 Process for preparing hydantoin therapeutic agents

Country Status (37)

Country Link
US (1) US4130714A (pt)
JP (1) JPS6035350B2 (pt)
AR (1) AR219531A1 (pt)
AT (1) AT357170B (pt)
AU (1) AU499518B1 (pt)
BE (1) BE867248A (pt)
CA (1) CA1088073A (pt)
CH (1) CH631455A5 (pt)
CS (1) CS200550B2 (pt)
DD (1) DD137107A5 (pt)
DE (2) DE2821966C2 (pt)
DK (1) DK147941C (pt)
EG (1) EG13691A (pt)
ES (1) ES470070A1 (pt)
FI (1) FI62838C (pt)
FR (1) FR2392024A1 (pt)
GB (1) GB1572688A (pt)
GR (1) GR68694B (pt)
HK (1) HK53981A (pt)
HU (1) HU177718B (pt)
IE (1) IE47273B1 (pt)
IL (1) IL54754A (pt)
IN (1) IN147854B (pt)
IT (1) IT1096306B (pt)
KE (1) KE3168A (pt)
LU (1) LU79685A1 (pt)
MY (1) MY8200156A (pt)
NL (1) NL7804158A (pt)
NO (1) NO150206C (pt)
NZ (1) NZ187334A (pt)
PH (1) PH13828A (pt)
PL (1) PL110460B1 (pt)
PT (1) PT68071B (pt)
SE (1) SE437375B (pt)
SU (1) SU873885A3 (pt)
YU (1) YU40829B (pt)
ZA (1) ZA782919B (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1088945A (en) * 1976-10-18 1980-11-04 Pfizer Limited Hydantoin derivatives as therapeutic agents
US4181728A (en) * 1978-11-16 1980-01-01 Pfizer Inc. Spiro-polycyclicimidazolidinedione derivatives
US4181729A (en) * 1979-03-21 1980-01-01 Pfizer Inc. Phenyl or phenoxy substituted spiro-imidazolidinedione derivatives
US4210667A (en) * 1979-04-19 1980-07-01 Pfizer Inc. Pharmaceutical preparations containing coumarin carboxylic acid derivatives
AU532110B2 (en) * 1979-11-13 1983-09-15 Ici Ltd. Spiro(imidazolidine-4,3:-indoline)-2,2:5-trione derivatives
US4248882A (en) * 1980-02-12 1981-02-03 Pfizer Inc. Treating diabetes-associated complications with hydantoin amines
US4286098A (en) * 1980-03-28 1981-08-25 Pfizer Inc. Process for the preparation of chiral hydantoins
JPS5745185A (en) * 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
US4419521A (en) * 1981-11-12 1983-12-06 Pfizer Inc. 6-Halo-4-chromanamines useful as intermediates to make chiral hydantoins
JPS58124788A (ja) * 1982-01-20 1983-07-25 Eisai Co Ltd 光学活性ヒダントイン誘導体，その製造方法ならびにそれを含有する治療用薬剤
US4438272A (en) 1982-04-15 1984-03-20 Alcon Laboratories, Inc. Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones
US4540700A (en) * 1982-04-15 1985-09-10 Alcon Laboratories, Inc. Treatment of diabetic complications with certain spiro-imidazolidine-diones
US4436745A (en) 1982-04-15 1984-03-13 Alcon Laboratories, Inc. Method of inhibiting aldose reductase activity
US4464385A (en) * 1982-04-15 1984-08-07 Alcon Laboratories, Inc. Treatment of diabetic complications with hydantoins
US4431828A (en) * 1982-11-10 1984-02-14 Pfizer Inc. Regeneration of 6-fluoro-4-chromanone from by-products in the synthesis of sorbinil
US4528387A (en) * 1982-11-10 1985-07-09 Pfizer Inc. Sorbinil by optical resolution of precursor 6-fluoro-4-ureidochroman-4-carboxylic acid
US4556670A (en) * 1982-12-06 1985-12-03 Pfizer Inc. Spiro-3-hetero-azolones for treatment of diabetic complications
US4474967A (en) * 1983-04-27 1984-10-02 Pfizer Inc. 8-Deutero and 8-tritio-substituted derivatives of D-4S-6-fluoro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione
US4537892A (en) * 1983-09-14 1985-08-27 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase
US5153211A (en) * 1983-09-14 1992-10-06 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase
EP0159143B1 (en) * 1984-03-23 1987-12-16 Pfizer Inc. Spiro-indenes and spiro-1,2-dihydro-naphthalenes for treatment of diabetic complications
US4717725A (en) * 1984-04-11 1988-01-05 Alcon Laboratories, Inc. Ophthalmic wound healing with aldose reductase inhibitors
US4600717A (en) * 1984-04-11 1986-07-15 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in ophthalmic wound healing
JPH06772B2 (ja) * 1984-07-09 1994-01-05 鐘淵化学工業株式会社 ３―（４―フルオロフエノキシ）プロピオニトリルを用いる６―フルオロ―４―クロマノンの製造法
US4680306A (en) * 1984-07-20 1987-07-14 Pfizer Inc. Sprio-imidazolones for treatment of diabetes complications
WO1986001107A1 (en) * 1984-08-14 1986-02-27 Pfizer Inc. Tetracyclic spiro-hydantoin aldose reductase inhibitors, compositions and methods of making
EP0172719B1 (en) * 1984-08-20 1988-09-21 Pfizer Inc. Process for the production as asymmetric hydantoins
US4620019A (en) * 1984-08-23 1986-10-28 Pfizer Inc. S-6-fluoro-4-aminochroman-4-carboxylic acid derivatives useful as intermediates for sorbinil
US4609663A (en) * 1984-09-11 1986-09-02 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in glaucoma therapy
US4551542A (en) * 1984-09-26 1985-11-05 Pfizer Inc. Regeneration of 6-fluoro-4-chromanone from 6-fluoro-4-ureidochroman-4-carboxylic acid
US5340829A (en) * 1984-11-20 1994-08-23 Washington Research Foundation Immunoregulatory agents
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
JPS61200991A (ja) * 1985-03-04 1986-09-05 Sanwa Kagaku Kenkyusho:Kk スピロ―３―ヘテロアゾリジン化合物、その製法及びそれを有効成分とする糖尿病合併症の予防及び治療剤
WO1986007353A1 (en) 1985-06-14 1986-12-18 Pfizer Inc. Intermediate in the production of an asymmetric hydantoin
JPS627654U (pt) * 1985-06-26 1987-01-17
US4853410A (en) * 1986-01-17 1989-08-01 Pfizer Inc. Hydroxyacetic acid derivatives for the treatment of diabetic complications
JPS6357588A (ja) * 1986-08-28 1988-03-12 Sanwa Kagaku Kenkyusho Co Ltd ヒダントイン誘導体、その塩並びに該化合物を有効成分とする糖尿病合併症の予防及び治療剤
JPH01503460A (ja) * 1987-03-20 1989-11-22 アルコン　ラボラトリーズ、インコーポレイテツド 糖尿病における、インシュリン感受性を増強させるためのアルドース還元酵素阻害剤の使用
US4841079A (en) * 1987-08-07 1989-06-20 Pfizer, Inc. Process for the production of asymmetric hydantoins
US5006657A (en) * 1988-07-27 1991-04-09 Pfizer Inc. Intermediates in a resolution process for racemic spiro hydantoins
US4952694A (en) * 1988-07-27 1990-08-28 Pfizer Inc. Novel resolution process for racemic spiro-hydantoins
AU617541B2 (en) * 1988-10-20 1991-11-28 Wyeth Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
EP0536119A4 (en) * 1989-02-10 1993-08-04 Washington Research Foundation Immunoregulatory agents
US4980357A (en) * 1990-03-01 1990-12-25 Pfizer Inc. Azolidinedione derivatives
US5039672A (en) * 1990-04-05 1991-08-13 Pfizer Inc. Heterocyclic compounds as aldose reductase inhibitors
US5236945A (en) * 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
US5206367A (en) * 1992-02-18 1993-04-27 Pfizer Inc. Preparation of optically active spiro-hydantoins
CA2145640C (en) * 1992-09-28 2001-01-30 Banavara L. Mylari Substituted pyrimidines for control of diabetic complications
US5521208A (en) * 1993-07-29 1996-05-28 Alcon Laboratories, Inc. Compositions and methods for the treatment of the metabolically impaired and for improved compliance
ATE344046T1 (de) * 1997-04-15 2006-11-15 Csir Pflanzenextrakte mit appetitunterdrückender aktivität
GB2396815B (en) * 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
GB2363985B (en) * 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
EE200300249A (et) 2000-11-30 2003-10-15 Pfizer Products Inc. GABA agonistide ja aldoosreduktaasi inhibiitoritekombinatsioon
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
US8158667B2 (en) 2006-08-21 2012-04-17 Kador Peter F Topical treatment of cataracts in dogs
US8877717B2 (en) 2007-03-12 2014-11-04 Zadec Aps Anti-diabetic extract of rooibos
EP2139330B1 (en) 2007-03-23 2014-09-24 The Board of Regents of The University of Texas System Methods involving aldose reductase inhibitors
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
CA2822672C (en) 2010-12-23 2018-06-05 The Board Of Regents Of The University Of Texas System Methods for treating copd
UA118035C2 (uk) * 2013-10-07 2018-11-12 Сінгента Партісіпейшнс Аг Гербіцидні сполуки
US12090142B2 (en) 2018-02-22 2024-09-17 Board Of Regents, The University Of Texas System Combination therapy for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683718A (en) * 1952-01-11 1954-07-13 Searle & Co Spiro-[xanthene-9, 4'-imidazolidine]-2, 5-dione
DE1135915B (de) * 1961-06-29 1962-09-06 Asta Werke Ag Chem Fab Verfahren zur Herstellung neuer, antikonvulsiv wirksamer Spirohydantoine
CA1088945A (en) * 1976-10-18 1980-11-04 Pfizer Limited Hydantoin derivatives as therapeutic agents

Also Published As

Publication number Publication date
SU873885A3 (ru) 1981-10-15
CA1088073A (en) 1980-10-21
DE2821966C2 (de) 1983-06-01
IN147854B (pt) 1980-07-19
ES470070A1 (es) 1979-01-01
DE2858042C2 (de) 1983-11-24
DE2821966A1 (de) 1978-11-30
MY8200156A (en) 1982-12-31
LU79685A1 (fr) 1979-12-06
GR68694B (pt) 1982-02-01
IE47273B1 (en) 1984-02-08
KE3168A (en) 1981-11-06
IT7823672A0 (it) 1978-05-22
IE781015L (en) 1978-11-23
GB1572688A (en) 1980-07-30
HK53981A (en) 1981-11-13
IT1096306B (it) 1985-08-26
EG13691A (en) 1982-12-31
FI62838B (fi) 1982-11-30
PT68071A (en) 1978-06-01
SE437375B (sv) 1985-02-25
JPS6035350B2 (ja) 1985-08-14
IL54754A0 (en) 1978-07-31
HU177718B (en) 1981-12-28
NO150206B (no) 1984-05-28
YU116978A (en) 1983-02-28
CH631455A5 (fr) 1982-08-13
SE7803626L (sv) 1978-11-24
ZA782919B (en) 1979-06-27
IL54754A (en) 1982-04-30
AR219531A1 (es) 1980-08-29
NZ187334A (en) 1984-04-27
NO781769L (no) 1978-11-24
BE867248A (fr) 1978-11-20
CS200550B2 (en) 1980-09-15
PL206826A1 (pl) 1979-04-23
YU40829B (en) 1986-06-30
FR2392024B1 (pt) 1981-07-24
NL7804158A (nl) 1978-11-27
DK147941B (da) 1985-01-14
FI781613A (fi) 1978-11-24
AT357170B (de) 1980-06-25
JPS53144575A (en) 1978-12-15
PH13828A (en) 1980-10-07
AU499518B1 (en) 1979-04-26
FR2392024A1 (fr) 1978-12-22
US4130714A (en) 1978-12-19
FI62838C (fi) 1983-03-10
PL110460B1 (en) 1980-07-31
ATA365378A (de) 1979-11-15
DK226778A (da) 1978-11-24
NO150206C (no) 1984-09-05
DD137107A5 (de) 1979-08-15
DK147941C (da) 1985-08-26

Similar Documents

Publication Publication Date Title
PT68071B (en) Process for preparing hydantoin therapeutic agents
CS194833B2 (en) Process for preparing azoles
PT68126A (en) Process for preparing therapeutic agents derivatives of phthalazine
HU179983B (en) Process for preparing nitroimidazole derivatives
GB2004493B (en) Process for preparing aluminus
PT68834A (en) Process for preparing therapeutic agents
PT67164A (en) Process for the preparation of hydantoin derivatives as therapeutic agents
GB2011899A (en) Process for preparing vincadifformine
ZA781511B (en) Process for therapeutic treatment
PT73835B (en) Process for preparing imidazolylpyridine therapeutic agents
YU279178A (en) Process for preparing 3-iodo-and 3-bromo-rifamycin s
DE2857617D1 (en) Process for the preparation of imidazoles
DE2860177D1 (en) Process for preparing acetylaminobenzenes
DE2860421D1 (en) Process for preparing 1-amino-2-sulfo-4-bromanthraquinone
DE2860171D1 (en) Process for preparing 1-amino-2-sulfo-4-bromo-anthraquinone
PT71399A (en) Process for preparing pyridylaminotriazole therapeutic agents
PT68034B (en) Process for preparing nitroimidazole antimicrobial agents
GB2011394B (en) Process for the preparation of methyliminiosobutyrate hydrochloride
DE2861557D1 (en) Process for preparing hydantoins and compounds obtainable by this process
JPS53101313A (en) Process for preparing alkylisocyanate
PT68876A (en) Process for preparing n-chloroimides
ZA786893B (en) Process for preparing n-chloroimides
JPS5385889A (en) Process for preparing urushiolllike substance
JPS53132562A (en) Process for preparing 11methyll55semicarbazidee66 hydroxyindole
GB2009736B (en) Process for preparing 7-amino-cephalosporins